New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Second Quarter 2019 Financial Results
August 07, 2019 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Review of Potential Strategic Transactions
April 15, 2019 16:30 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
March 28, 2019 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease
January 24, 2019 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...